Zydus Cadila’s Net Profit up by 18% in Q3 on a sequential basis


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Zydus Cadila’s
Zydus Cadila's net profit excluding exceptional items for the quarter was up 18% q-o-q to Rs. 375 crores.

For the third quarter ended December 31, 2019, Zydus Cadila reported consolidated revenues of Rs.3638 crores. Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs. 693 crores, up 11% on a q-o-q basis. Net profit excluding exceptional items for the quarter was up 18% q-o-q to Rs. 375 crores.


The company’s formulations business in the US posted sales of Rs. 1675 crores, up 16% on a q-o-q basis. The Indian branded human formulations business of the company grew by 9.6% on a y-o-y basis. The company’s rest of the world business comprising of multiple emerging markets grew by 21% on a sequential basis.


During the quarter, the company launched 9 new products in the US which included a Day One launch. The Company filed 14 additional ANDAs with the USFDA taking the cumulative number of filings to 386. The Company received 8 new product approvals (incl. 2 tentative approvals) from the USFDA during the quarter.


During the quarter, the company launched the oral anti-diabetic agent, Vinglyn (Vildagliptin) and Vinglyn M (Vildagliptin plus Metformin) in India. Vinglyn is now one of the most affordable brands of Vildagliptin for diabetic patients in India.

Making brisk progress on the research front, the company filed the New Drug Application (NDA) of Saroglitazar Mg in Non-alcoholic Steatohepatitis (NASH) with the Drug Controller General of India (DCGI). This is the first NDA filed with any regulatory authority across Asia and only the second across the globe for NASH indication. During the quarter, the Company made a presentation of Saroglitazar in NAFLD at the American Association for the study of Liver Diseases (AASLD), Boston as the molecule achieved statistically significant improvement compared to placebo in primary  endpoint. The paper was selected as a part of Best of NAFLD/ NASH debrief given by AASLD.


The company also announced the second Phase III DREAM-D trials of Desidustat, an Investigational New Drug (IND) targeted at treating anemia in dialysis dependent CKD patients, during the quarter.


During the quarter, the Company received regulatory permission to conduct Phase I clinical trials for Hepatitis A and Hepatitis E Vaccines. Dossiers were also submitted to the DCGI for the Marketing Authorization of Pentavalent Vaccine.

Tags : #Zyduscadila #Q3results #Usfda #Medicircle

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026